about
Fixed-dose combination therapy for the prevention of cardiovascular diseaseFixed-dose combination therapy for the prevention of cardiovascular diseaseResource Effective Strategies to Prevent and Treat Cardiovascular DiseaseCoronary heart disease prevention: insights from modelling incremental cost effectivenessSecondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service FrameworkEvaluating national guidelines for prevention of cardiovascular disease in primary careA cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countriesCardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysisCoronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and womenFixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.Prevention of Hypertensive Disorders of Pregnancy: a Novel Application of the Polypill Concept.The polypill approach - An innovative strategy to improve cardiovascular health in Europe.Improving diabetes care: multi-component cardiovascular disease risk reduction strategies for people with diabetes in South Asia--the CARRS multi-center translation trial.Time trends in preventive drug treatment after myocardial infarction in older patientsAvailability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI dataRationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.Stroke Prevention: The Best Outcome after a Transient Ischemic Attack. Results from the Minnesota Stroke Registry and Opportunities to Improve Care.Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.Hormone replacement therapy: a time for pause.An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.Subclinical cardiovascular disease in type 2 diabetes mellitus: To screen or not to screen.Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis)The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in SeychellesDiabetes mellitus update.Understanding patients' experiences of treatment burden in chronic heart failure using normalization process theory.Perspectives on the management of coronary artery disease in India.Adverse drug reactions in special populations - the elderly.Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery.Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South KoreaCardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisitedPatterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in CanadaThe impact of prevention on reducing the burden of cardiovascular diseaseCardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart StudyStroke prevention in the high-risk patient.Scaling up chronic disease prevention interventions in lower- and middle-income countriesEssential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.How many cardiovascular events can be prevented with optimal management of high-risk Canadians?
P2860
Q24195065-059D955A-7A4C-4CFE-9A7D-B88983A41C08Q24198070-8C1E95D5-1691-431E-A5F6-CC4DA95BB5AAQ26768304-9147C0B2-642D-4064-BC76-9447A3AF9EA3Q28166294-0DDF797F-4703-45CF-92B7-6FD092D9BDE3Q28191878-98D443AB-6A5C-4730-8BA4-2DF8C6D6952BQ28191895-0F720856-AA72-47AE-BD10-1E6763654A02Q28196568-B1E0BD41-BE6F-42BF-BDE9-78498B6019ADQ28200196-92F648CA-8DBB-4499-839A-462E4B48DA75Q28210662-236CA788-AE98-4B18-B2C1-6E38C8807F5FQ30235416-BC99E5DF-F64B-4E1D-8C6E-C4B570D7957FQ30239945-B236D00F-E765-462D-B416-E8B3494552B4Q30383425-DCF9BCBE-8409-4EBD-9B79-575F3FC0563CQ30398270-80D873B1-F6F4-44AC-AAAC-BA4DAF4A0D60Q30532203-8AC8B085-DC5D-4537-984B-2354521D27ADQ33571940-7E45D6CD-36E4-49BA-8953-4EA268C5A73BQ33599245-F0DA1C6C-2EFA-44F4-B480-DEAE0E4B80A3Q33650346-29ED93FC-9001-4606-8DDA-303809FFC760Q33655118-32EA71A0-3C0D-4395-9B53-55E3056DF920Q33723567-EA958A8B-67D6-47DD-A208-C2791F2E0CEFQ33902183-8D01F703-B292-487B-A7A7-0F52FA3CDF94Q33925329-922A6B42-6015-499A-AA9F-E54C4A7EA6A0Q34138321-AA08032E-600F-499A-BD1C-D52AACABFA67Q34179368-3D49D609-F7F0-419C-88E1-8D07D352D5E2Q34240747-6F4A7EC6-9F7C-43F7-94CC-2462A3016441Q34533125-6959AFC1-5251-49C8-9138-5A552471D643Q34734618-40D24858-1196-4F5E-BD12-F87D17C1076CQ34808283-4217D654-CE18-495F-995C-FFF32A99C40EQ34958077-FC908C8A-0617-48F2-A58B-0CAD056ED229Q36057242-BADC72FE-3717-4A56-911D-CB1A768DDC2EQ36125513-A0B39909-2418-4F05-861C-B7DC258A780AQ36402654-1DEB5A7F-63F3-4FD7-9F4D-EAD8CC51AC19Q36593654-20E7A20A-E7B8-4581-A31E-590517C9EE24Q36662065-E2C7EF3C-BA03-4E68-9723-972D7BD4A854Q36794337-52F32C69-F1F7-4129-94BD-9F09197E9BD6Q36807520-99951898-8B9C-439A-81FA-C0EB898144E6Q36820614-D7B91A84-54A6-4C5C-9767-B55F27F7C71AQ36909266-68E49A7A-BFD5-40AF-AF76-D02451CB380CQ36939475-75FAEAEE-D93E-4FCE-AD4F-E7ECB12053FAQ36957089-8B7DDA41-534C-4684-AEFC-59B387C961E4Q37098243-64F61EF6-E272-4CE0-928C-6F31F0933AB0
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Two decades of progress in preventing vascular disease.
@ast
Two decades of progress in preventing vascular disease.
@en
Two decades of progress in preventing vascular disease.
@nl
type
label
Two decades of progress in preventing vascular disease.
@ast
Two decades of progress in preventing vascular disease.
@en
Two decades of progress in preventing vascular disease.
@nl
prefLabel
Two decades of progress in preventing vascular disease.
@ast
Two decades of progress in preventing vascular disease.
@en
Two decades of progress in preventing vascular disease.
@nl
P1433
P1476
Two decades of progress in preventing vascular disease.
@en
P2093
Salim Yusuf
P356
10.1016/S0140-6736(02)09358-3
P407
P577
2002-07-01T00:00:00Z